Knoll Considering Segard Plans; Sepsis Study Shows Small Mortality Benefit
Executive Summary
Knoll is considering the next step for its TNF inhibitor Segard, after one of two pivotal trials for sepsis showed a modest mortality benefit.
You may also be interested in...
Sepsis Pipeline Could Be Resuscitated With Narrower Trials, Researchers Propose
Sepsis trials designed with narrower enrollment criteria could allow treatment effects to emerge, countering the “signal to noise” problem that has plagued late-stage trials in sepsis, researchers suggest.
Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
Abbott is projecting strong growth for Synthroid in 2002 despite the phase-down of distribution required during FDA review of the NDA for the levothyroxine product
Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
Abbott is projecting strong growth for Synthroid in 2002 despite the phase-down of distribution required during FDA review of the NDA for the levothyroxine product